Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05790213 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contact updatedv9
  2. Primary completion date: Apr 1, 2026 to Dec 18, 2028
    • Start date: Aug 17, 2023 to May 5, 2025
    • Study completion date: Apr 1, 2028 to Dec 18, 2028
    v8
  3. Trial status: Suspended to Recruiting
    • Primary endpoints revised (3)
    • Site details revised
    v7
  4. Primary endpoints revised (3)v6 Show 6 more changesShow less
    • Sponsor's reason: Temporary Accrual Hold as Principal PI Moves Institutions and seeks additional funding to Suspended pending implementation of new amendment
    • Interventions: Androgen Deprivation Therapy (ADT) (Drug), Apalutamide Oral Product (Drug), Focal Therapy (Procedure) to Androgen Deprivation Therapy (ADT) (Drug), Focal prostate ablation (focal therapy) (Procedure)
    • Eligibility criteria shortened, about 357 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Collaborators shortened, about 2 words
    • Study title shortened, about 4 words
  5. Sponsor's reason: Temporary Accrual Hold as Principal PI Moves Institutions to Temporary Accrual Hold as Principal PI Moves Institutions and seeks additional fundingv5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Recruiting to Suspended Sponsor's reason: Temporary Accrual Hold as Principal PI Moves Institutions
    • Lead sponsor: University of Cincinnati to University of Chicago
    • Study site revised
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2023 to Aug 17, 2023
    • Site details revised
    v3
  3. Start date: Apr 1, 2023 to Jun 1, 2023
    • Eligibility criteria shortened, about 12 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).
Trial Details
NCT Number NCT05790213
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 57 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov